Fluorescent Amyloid Binding Agents for Diagnosis of Alzheimer's Disease
Simple synthesis and chemistries amenable to modification and production at large scales. Fluorescence profile optimized for in vivo characterization of amyloid deposits using existing and widely accessible imaging instruments. These probes may be used for the monitoring of disease progression in the development of new therapeutic treatments.
Fluorescent probes are compatible with in vivo fluorescence imaging instruments. Generally relevant for the early diagnosis of diseases characterized by amyloid aggregates, such as Alzheimer’s, Parkinson, Huntington disease, and rheumatoid arthritis.
A common structural feature of known amyloid-binding agents is an electronically-polarized, extended aromatic system that is inherent to a family of fluorescent probes known as molecular rotors. Features of molecular rotors, which inherently decrease the non-radiative decay rate and increase fluorescence emission upon binding to aggregated beta-amyloids, were incorporated into a general design of novel, amyloid-binding agents.
Patent Number: US20120302603A1
Application Number: US13515239A
Inventor: Yang, Jerry | Theodorakis, Emmanuel A.
Priority Date: 10 Dec 2009
Priority Number: US20120302603A1
Application Date: 9 Aug 2012
Publication Date: 29 Nov 2012
IPC Current: C07C025543 | A61K0031277 | A61K0031451 | A61P002528 | C07D0295155 | G01N002164 | G01N0033566
US Class: 514319 | 436501 | 514521 | 546205 | 558402 | 558403
Assignee Applicant: The Regents of the University of California
Title: AMYLOID BINDING AGENTS
Usefulness: AMYLOID BINDING AGENTS
Summary: For treating a disease caused by accumulation of amyloids in a subject, for treating Alzheimer's disease, bovine spongiform encephalopathy (BSE), Parkinson's disease, Huntington's disease, Down's Syndrome, dementia with Lewy body, or amyotrophic lateral sclerosis (ALS) (all claimed).
Novelty: New 2-cyano-acrylic acid derivatives useful for treatment of e.g. Alzheimer's disease, bovine spongiform encephalopathy, or Parkinson's disease
化工/材料
化工/材料应用
8940918
State Of Development Proprietary methods were used to identify, synthesize, and characterize seven, novel compositions of matter. Development included in vitro evaluation for specifications relevant to use in clinical practice, including: solubility, fluorescence characteristics, ability to cross the blood-brain barrier, binding constants, and capability to detect amyloidosis in brain tissue. Intellectual Property Info US and numerous foreign rights available for licensure in some fields. US application at link, below. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 20849/2010-162-0 Related Cases 2010-162-0, 2006-105-1, 2006-105-2, 2006-105-4, 2006-105-3, 2007-018-1, 2007-018-2
美国
